+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peptide Synthesis Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • PDF Icon


  • 110 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4987037

The peptide synthesis market is expected to register a CAGR of 5.5 % over the forecast period.

In the current COVID-19 situation, peptides are increasingly being developed and repurposed in search of therapeutics for the treatment of COVID-19. In February 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. As per the data on Clinical Trials.gov, in May 2020, 21 peptide drugs were in the development for the treatment of COVID-19, including 15 synthetic peptides for acute respiratory distress syndrome (ARDS), a life-threatening condition where the lungs cannot provide the body’s vital organs with enough oxygen, and other respiratory illnesses caused by SARS-Cov-2 infection.

The major growth of the market is a steep rise in the adoption of peptides in the pharmaceutical and consumer healthcare industries. The peptides have a wide range of applications in the treatment of various lifestyle disorders, such as cancers, diabetes, and obesity. The increasing incidence of these metabolic and lifestyle disorders is paving the way for the application of peptide therapeutics in oncology and metabolic disorders. According to the International Diabetes Federation report published in 2020, around 463 million people were living with diabetes in 2019, and by 2045, the prevalence will reach 700 million. Among the prevalence, type 2 diabetes is the most common type of diabetes, accounting for around 90% of diabetes globally. Diabetes mellitus (type 2 diabetes) is a group of metabolic disorders of carbohydrate metabolism. Several peptide therapies, such as Glucagon-like peptide-1amide, release postprandially that stimulates insulin secretion, and they are popular in pancreatic therapy. Thus, due to the rise in the volume of the patient pool with Type 2 diabetes, the demand for peptides is expected to increase, which is likely to fuel the market over the forecast period. The increased research activities and novel product approvals due to the rise in funding for R&D and the advantages of advanced peptide synthesizers have further boosted the growth of the peptide synthesis market throughout the period. For instance, in 2018, Novartis and Amgen received approval in European Union countries for Aimovig (erenumab), a calcitonin gene related-peptide inhibitor that helps in the treatment of migraine in adults. As per the Novartis, patients administered with erenumab during the clinical studies were reported with almost 50% reduction of migraine attacks. Thus, such significant developments in peptide drugs are expected to boost the demand.

Key Market Trends

Pharmaceutical and Biotechnology Companies are Expected to Hold a Significant Market Share Over the Forecast Period

Based on the end-user, pharmaceutical and biotechnology companies are expected to hold a significant market due to the increasing adoption of peptides for therapeutic development in this industry. The research and developments of peptide therapies are increasing, as they are cost-effective, efficient, and have lower toxicity. These peptides are also a major part of the COVID-19 related research these days. Swiss-based Relief Therapeutics is conducting an FDA-approved clinical trial, which is part of the FDA’s Coronavirus Treatment Acceleration Program (CTAP), at New York University Langone (NYU Langone Health) to assess the effect of Aviptadil, a patented synthetic form of a human vasoactive intestinal polypeptide (VIP) for COVID-19-related ARDS. New oral drugs are being developed by various pharmaceutical and biotechnology companies, which is expected to boost the demand for this segment.

For instance, in 2019, the US FDA approved Rybelsus oral tablets for controlling blood sugar in type-2 diabetes patients. It is a glucagon-like peptide (GLP-1) receptor protein treatment developed by Novo Nordisk. Also, in November 2019, AstraZeneca announced large-scale initiatives in China to advance global research and development (R&D) for innovative medicines, including peptide therapies. All these developments are expected to propel the growth of the pharmaceutical and biotechnology end-user segment.

The graph below suggests that the prevalence of diabetes is increasing in the world, which is also fueling the demand for the treatment of this metabolic disorder, which in turn is expected to drive market growth.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the overall peptide synthesis market throughout the forecast period. The dominance is due to the growing prevalence of obesity with a rise in sedentary deskbound lifestyle, and lack of proper diet and physical activity resulting in various chronic diseases like diabetes in the United States necessitated the efficient treatment. For instance, according to the International Diabetes Federation in 2019, about 48 million adults in North America live with diabetes, and they are expected to continue resulting in higher demand for peptide therapeutics driving the market in the region.

Furthermore, the increased availability of advanced healthcare infrastructure and huge investments by the key players in this region to develop new peptide synthesis technologies are also likely to fuel the market growth. A favorable earlier approval of peptide drugs owing to the accelerated drug approval initiative by the USFDA is also likely to fuel the market growth in this region across the forecast period, contributing to its outstanding market share in the global peptide synthesis market.

Competitive Landscape

The peptide synthesis market is moderately competitive, with several major players. Some companies are expanding their market position by adopting various strategies, such as acquisitions, mergers, and research collaborations, while others are introducing new products to maintain their market share. In May 2019, CEM Corporation launched Liberty PRO, the world’s first-ever large-scale automated microwave peptide synthesizer. The system can synthesize 1 kg of crude peptide per batch utilizing reaction vessel, with sizes up to 15 liters with unmatched purity, speed, and waste reduction fueling the market revenue share. A few of the major players currently dominating the industry in terms of revenue are AAPPTec, CSBio Company Inc., Biotage AB, Bachem Holding AG, and CEM Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Investments Along with Huge Funding for R&D of Genomics and Proteomics in Bio-pharmaceutical Industry
4.2.2 Rapid Technological Advancements in Peptide Synthesizers and Strong Peptide Therapeutics Pipeline
4.3 Market Restraints
4.3.1 Issues Pertaining to Large-scale Peptide Synthesis and Lack of Robust Distribution Network
4.3.2 Challenges in Development of Peptides and Instability of the Peptides
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Technology
5.1.1 Solid-Phase
5.1.2 Liquid-Phase
5.1.3 Hybrid and Recombinant
5.2 By Product
5.2.1 Equipment
5.2.2 Reagents and Consumables
5.2.3 Other Products
5.3 By End-User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Contract Development and Manufacturing Organization (CDMO)
5.3.3 Academic and Research Institutes
5.4 By Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Rest of the World
6.1 Company Profiles
6.1.1 AAPPTec
6.1.2 Anaspec Inc.
6.1.3 Bachem Holding AG
6.1.4 Biotage AB
6.1.5 CEM Corporation
6.1.6 CSBio Company Inc.
6.1.7 Gyros Protein Technologies AB
6.1.8 Merck KGaA
6.1.9 Vivitide(Wheelock Partners LLC)
6.1.10 Thermo Fisher Scientific

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AAPPTec
  • Anaspec Inc.
  • Bachem Holding AG
  • Biotage AB
  • CEM Corporation
  • CSBio Company Inc.
  • Gyros Protein Technologies AB
  • Merck KGaA
  • Vivitide(Wheelock Partners LLC)
  • Thermo Fisher Scientific